Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

October 19, 2023

Study Completion Date

March 14, 2024

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Ruxolitinib cream

Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

DRUG

Vehicle cream

Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

Trial Locations (20)

19462

Dermatology Associates of Plymouth Meeting, Plymouth Meeting

33486

Skin Care Research, Llc Scr Hollywood, Boca Raton

33613

Forcare Clinical Research, Tampa

37130

International Clinical Research Tennessee Llc, Murfreesboro

48084

Revival Research Institute, Llc Troy, Troy

70115

Delricht Research, New Orleans

70809

Delricht Research, Baton Rouge

78213

Progressive Clinical Research, San Antonio

78660

Austin Institute For Clinical Research Aicr Pflugerville, Pflugerville

85006

Medical Dermatology Specialists Phoenix, Phoenix

92708

First Oc Dermatology, Fountain Valley

99202

Dermatology Specialists of Spokane, Spokane

30060-1047

Marietta Dermatology the Skin Cancer Center Marietta, Marietta

02215

Beth Israel Deaconess Medical Center, Boston

10012-1354

Dr Bobby Buka, Md Greenwich Village, New York

R3M 3Z4

Wiseman Dermatology Research Inc, Winnipeg

N6H 5L4

Dr.Wei Jing Loo Medicine Professional Corp, London

L3P 1X2

Lynderm Research Inc, Markham

K9J 5K2

Skin Centre For Dermatology, Peterborough

N8W 1E6

Xlr8 Medical Research, Windsor

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT05635838 - Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter